Related Experiment Videos
Interferons in precancer and cancer prevention: where are we?
1Associazione Nazionale Tumori (ANT), Bologna, Italy.
Abstract:
Clinical research on interferons (IFN) still focuses on the treatment of advanced cancer. The research strategy eventually must be reevaluated. The cellular minimal deviations that are seen in early phases of carcinogenesis might be the most rational target for immune interventions. That biologic response modifiers have considerable capacity to prevent induction and development of malignant neoplasias has been demonstrated in several animal systems. Even the few clinical studies available at present on the treatment of preneoplastic lesions with IFN have definitely shown more success than those involving treatment of advanced tumors. In addition, there is experimental evidence that IFN might be suitable candidates for immunoprevention. The major problems hampering a wider application of IFN in immunoprevention is that they cause adverse effects. Unfortunately, we do not know much about the specific mechanisms involved in the immune control of human tumor development during the initial and the latency phases of carcinogenesis. More research is needed in this area. In this article the state of the art of using IFN for treating preneoplastic lesions is reviewed, and also we report some of our experimental results on IFN and anticancerogenesis.
Insights
Interferons (IFN) show promise in preventing cancer by targeting early cellular changes, offering a new strategy beyond treating advanced tumors. Further research is needed to understand mechanisms and mitigate adverse effects for effective immunoprevention.
Area of Science:
- Oncology
- Immunology
- Cancer Prevention
Background:
- Current interferon (IFN) research primarily targets advanced cancers, necessitating a strategic reevaluation.
- Early-stage carcinogenesis, characterized by minimal cellular deviations, presents a rational target for immune interventions.
Purpose of the Study:
- To review the current use of interferons (IFN) in treating preneoplastic lesions.
- To present experimental findings on interferons (IFN) in anticancerogenesis.
- To explore the potential of interferons (IFN) for cancer immunoprevention.
Main Methods:
- Review of existing clinical studies on IFN treatment for preneoplastic lesions.
- Presentation of experimental results concerning IFN and anticancerogenesis.
- Discussion of animal system data demonstrating the efficacy of biologic response modifiers in preventing neoplasia.
Main Results:
- Clinical studies on treating preneoplastic lesions with IFN show greater success than treating advanced tumors.
- Animal models indicate that biologic response modifiers can prevent malignant neoplasia development.
- Experimental evidence suggests IFN's potential suitability for cancer immunoprevention.
Conclusions:
- Interferons (IFN) offer a promising therapeutic avenue for preneoplastic lesions and cancer immunoprevention.
- Understanding the immune control mechanisms during early carcinogenesis is crucial for advancing IFN applications.
- Adverse effects of IFN require further investigation to enable wider clinical use in cancer prevention.